树突状细胞疫苗对胃癌患者术后免疫功能影响的初步观察

目的探讨树突状细胞(DCs)疫苗治疗胃癌术后患者的临床疗效。方法采用外周血单个核细胞及自体肿瘤抗原在体外制备DCs疫苗,将50例胃癌术后患者随机分为两组,对照组予以常规化疗;疫苗治疗组常规化疗2周后进行DCs疫苗皮下注射,每周1次、共4次。治疗前后检测患者外周血T淋巴细胞亚群及NK细胞百分比的变化,观察DCs疫苗治疗的初步临床效果及不良反应。结果疫苗治疗组外周血T淋巴细胞亚群及NK细胞百分比在DCs注射2周后开始上升,4周后上升至最高值犤CD3 (71.2±9.8)%,CD4 /CD8 (1.76±0.24)%,NK细胞(13.5±2.6)%犦,第8周下降;与同期对照组犤CD3 (58.8±9.2)%,CD4 /CD8 (1.26±0.29)%,NK细胞(10.8±2.3)%犦相比,差异有显著性意义(P<0.05)。疫苗治疗组患者血常规及肝肾功能检测均正常,未出现明显毒副反应。结论DCs疫苗可明显改善胃癌术后患者T细胞亚群及NK细胞百分比,临床应用无明显不良反应。

Clinical effects of dendritic cell vaccine on postoperative patients with gastric cancer

Objective To investigate clinical effects of dendritic cell vaccine on postoperative patients with gastric cancer. Methods Dendritic cells were produced and pulsed with self tumor antigens in vitro. Fifty patients with gastric cancer were divided into 2 groups randomly. The postoperative patients in treatment group received DCs vaccination four times at an interval of 7 days after chemotherapy. The control group only received chemotherapy. T lymphocyte subtypes and NK cell in peripheral blood of two group patients were analyzed and clinical effects were observed. Results The levels of CD4 /CD8 and NK cell in the DCs group increased 2 weeks after vaccination and reached peak 4 weeks after vaccination, while those of the control group had no significant changes. No side effects were observed. Conclusion Dendritic cell vaccine can improve T cell subtypes and NK cell ratio of the postoperative patients with gastric cancer.